Table 3. Outcome results according to ERCC1 polymorphisms in P vs non-P regimens.

	ERCC1 8092		ERCC1 C118T
	G/GNo. 40	T/−No. 58	C/CNo. 22	T/−No. 69
RR (%)
P	33.3	46.4	40	41.7
Non-P	21.1	26.7	33.3	24.2
OR (95% CI)	1.78 (0.42–7.54)	2.39 (0.79–7.26)	1.46 (0.25–8.52)	2.13 (0.75–6.04)
P-valuea	0.752		0.720
Median PFS (mos)
P	7.3 (3.7–12.4)	6.4 (2.8–7.4)	8.7 (2.1–17.5)	5.5 (2.8–7.1)
Non-P	8.0 (3.8–13.4)	4.1 (2.9–7.2)	4.1 (2.5–9.4)	6.7 (4.0–8.0)
HR (95% CI)	0.90 (0.48–1.70)	0.81 (0.48–1.37)	0.61 (0.26–1.41)	1.13 (0.70–1.82)
P-valuea	0.805		0.213
Median OS (mos)
P	9.8 (4.8–18.2)	10.5 (5.6–15.7)	15.3 (4.4–33.8)	8.0 (3.7–15.4)
Non-P	14.5 (9.3–23.9)	11.2 (6.3–15.6)	16.3 (8.0–36.8)	13.4 (9.7–19.8)
HR (95% CI)	1.12 (0.60–2.11)	1.12 (0.65–1.92)	0.89 (0.36–2.18)	1.50 (0.93–2.45)
P-valuea	0.998		0.316

Abbreviations: CI=confidence interval; ERCC1=excision repair cross-complementing 1; HR=hazard ratio; mos=months; non-P=non-platinum; OR=odds ratio; OS=overall survival; P=platinum; PFS=progression-free survival; RR=response rate.

^aTest of interaction.